Y-27632 Dihydrochloride: A Selective ROCK Inhibitor for Cytoskeletal and Stem Cell Studies

Executive Summary: Y-27632 dihydrochloride is a potent, cell-permeable inhibitor targeting ROCK1 and ROCK2, with an IC₅₀ of ~140 nM and a K_i of 300 nM respectively, offering over 200-fold selectivity against related kinases (ApexBio). It disrupts Rho-mediated stress fiber formation, modulates cell cycle progression, and is widely validated in cell proliferation and tumor invasion assays (Mishra et al., 2024). The compound demonstrates excellent solubility in DMSO, ethanol, and water, and is stable for several months at -20°C. Y-27632’s translational value extends to stem cell and cancer research, offering a reliable tool for dissecting Rho/ROCK signaling pathways (Strategic Modulation of the Rho/ROCK Signaling Pathway). Misapplication or storage errors can compromise activity, emphasizing the need for precise workflow integration.

Biological Rationale

Rho-associated protein kinases (ROCK1 and ROCK2) regulate actin cytoskeleton dynamics, cell contractility, migration, and cell cycle progression. Dysregulation of the Rho/ROCK pathway is implicated in diverse pathologies including cancer metastasis, neurodegeneration, and fibrosis (Mishra et al., 2024). Early endo-lysosomal dysfunction, a hallmark of neurodegenerative diseases such as Alzheimer’s, involves cytoskeletal and trafficking defects potentially modulated by ROCK activity. Targeted inhibition of ROCK kinases enables researchers to dissect these pathways and test therapeutic hypotheses in cell and animal models.

Mechanism of Action of Y-27632 dihydrochloride

Y-27632 dihydrochloride acts as an ATP-competitive inhibitor, binding directly to the catalytic domain of ROCK1 and ROCK2. This interaction blocks phosphorylation of downstream effectors, such as myosin light chain (MLC), LIM kinase, and cofilin, thereby inhibiting actin-myosin contractility and stress fiber formation. The compound’s selectivity is illustrated by >200-fold reduced inhibition of kinases like PKC, PKA, MLCK, and PAK at relevant concentrations (ApexBio). Inhibition of the Rho/ROCK axis results in decreased cell contractility, altered cell shape, and modulated cell cycle progression—particularly at the G1/S checkpoint. In stem cells, Y-27632 supports viability by preventing dissociation-induced apoptosis.

Evidence & Benchmarks

• Y-27632 inhibits ROCK1 with an IC₅₀ of ~140 nM and ROCK2 with a K_i of 300 nM under in vitro kinase assay conditions (ApexBio, product page).
• Demonstrates >200-fold selectivity against PKC, PKA, MLCK, and PAK, confirmed in kinase profiling assays (ApexBio).
• Reduces proliferation of prostatic smooth muscle cells in vitro in a concentration-dependent manner (10–100 μM, 37°C, 5% CO₂) (Mishra et al., 2024).
• In vivo, Y-27632 decreases tumor invasion and metastasis in mouse xenograft models (10 mg/kg/day i.p. for 2 weeks) (Strategic Modulation of the Rho/ROCK Signaling Pathway).
• Enhances survival rates of human iPSC-derived neurons by >60% after single-cell dissociation when used at 10 μM in standard culture media (Unlocking Translational Potential).
• Solubility: ≥111.2 mg/mL in DMSO, ≥17.57 mg/mL in ethanol, ≥52.9 mg/mL in water, at room temperature; solubility increases with gentle warming or sonication (ApexBio).

Applications, Limits & Misconceptions

Y-27632 dihydrochloride is extensively used in the following research areas:

• Cytoskeletal Studies: Disruption of Rho-mediated actin stress fibers in fibroblasts, smooth muscle, and epithelial cells.
• Stem Cell Biology: Enhancement of human pluripotent stem cell survival after dissociation, supporting clonal expansion and genome editing workflows.
• Cancer Research: Inhibition of ROCK-dependent tumor cell migration, invasion, and metastasis.
• Neurobiology: Investigation of neuronal migration, axon outgrowth, and endo-lysosomal trafficking, including in Alzheimer’s disease models (Mishra et al., 2024).

Building on prior reviews such as Y-27632 Dihydrochloride: Selective ROCK Inhibition for Advanced Research, this article provides updated benchmarks and practical storage/solubility insights for robust protocol design.

Common Pitfalls or Misconceptions

• Non-selectivity at high concentrations: Doses above 50–100 μM may cause off-target effects on other kinases; always titrate for minimal effective concentration (ApexBio).
• Not a universal cell survival factor: Y-27632 is effective for human pluripotent stem cells, but not all primary or differentiated cells respond similarly; some cell types may not benefit or could be adversely affected (Unlocking Translational Potential).
• Inapplicability for chronic treatments: Long-term exposure (days to weeks) can induce compensatory mechanisms, reducing efficacy or causing cytotoxicity.
• Storage errors compromise potency: Repeated freeze-thaw cycles or extended storage in solution (>2 weeks) at room temperature degrade activity; always prepare fresh aliquots and store desiccated at ≤4°C.
• Not a direct modulator of SORL1 or endo-lysosomal proteins: Effects on trafficking are indirect, via cytoskeletal modulation and not by altering SORL1 expression or function (Mishra et al., 2024).

Workflow Integration & Parameters

• Solubility optimization: Dissolve Y-27632 dihydrochloride at ≥111.2 mg/mL in DMSO, ≥17.57 mg/mL in ethanol, or ≥52.9 mg/mL in water; use gentle warming (37°C) or brief sonication for rapid dissolution (ApexBio).
• Stock storage: Store solid at ≤4°C, desiccated; aliquot stock solutions and store at –20°C. Avoid repeated freeze-thaw cycles.
• Working concentrations: For cell survival and cytoskeletal studies, 5–20 μM is typical; for cancer invasion assays, use 10–50 μM, adjusting based on cell type and assay duration.
• Controls: Always include vehicle (DMSO/ethanol/water) controls at matching concentrations.

This article extends the protocol guidance from Unlocking Translational Potential: Precision ROCK Inhibition by adding updated solubility and storage parameters validated in recent cell and animal studies.

Conclusion & Outlook

Y-27632 dihydrochloride (A3008) is a validated, selective tool for probing Rho/ROCK signaling in cytoskeletal, stem cell, and cancer research. Its robust selectivity and solubility profile support reproducible assay design and translational workflows. Future research may further clarify its role in disease models involving cytoskeletal and trafficking defects, but careful titration and storage remain essential for optimal results. For more details and purchasing information, visit the Y-27632 dihydrochloride product page.

For further perspective on translational and neuroepigenetic implications, see Y-27632 Dihydrochloride: Unlocking Neuroepigenetic and Cancer Research Frontiers, which explores areas beyond standard cytoskeletal assays.